The Quantellect read.As of Nov 19, 2026, 16 active firms cover Inspire Medical Systems Inc: 4 rate it Buy or better, 10 sit at Neutral, and 2 rate it Sell or worse, a neutral consensus. Targets range widely, $39.00 to $97.00 (about 2.5x), a sign of real disagreement on valuation. The average target of $67.07 sits 15% above the current $58.12. Sentiment has cooled somewhat, with Sell ratings rising from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.13 next quarter toward $1.50 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 active firms
Neutral
Strong Buy00%
Buy425%
Neutral1063%
Sell213%
Strong Sell00%
Based on 16 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$67.07
+15.4% upside
Average target across 14 active firms as of Nov 19, 2026 vs $58.12 current
Highest Target$97.00
Average Target$67.07
Lowest Target$39.00
Detailed analyst forecasts for INSP
Showing 1–16 of 16 named analysts shown · 16 active firms in the rating projection
As of Nov 19, 2026, 4 of 16 active firms rate INSP a Buy (10 Neutral, 2 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
INSP EPS & revenue forecast
EPS · NEXT QUARTER
$0.13
Range $-0.13 – $0.34 · 10 analysts · +27% YoY
Next period, 10 analysts expect Inspire Medical Systems Inc to earn $0.13 a share (range $-0.13 – $0.34), versus $0.10 a year earlier. Full-year consensus is $1.30, growing to $1.50 the year after.
REVENUE · NEXT QUARTER
$192.4M
Range $184.8M – $200.3M · 10 analysts · -6% YoY
Revenue is expected to reach $192.4M (range $184.8M – $200.3M), -6.0% year-over-year. Full-year consensus is $855.4M, rising to $877.8M next year.
Top analysts covering Inspire Medical Systems Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INSP.
#1
Anthony Petrone
Mizuho · Rank #121
Buy
$75.00+29.0% to target
Overall win rate
45%
+ Follow
#2
Jonathan Block
Stifel · Rank #294
Buy
$85.00+46.2% to target
Overall win rate
36%
+ Follow
#3
Frank Takkinen
Lake Street · Rank #514
Buy
$150.00+158.1% to target
Overall win rate
27%
+ Follow
#4
Richard Newitter
Truist Securities · Rank #532
Neutral
$78.00+34.2% to target
Overall win rate
30%
+ Follow
#5
LB
Larry Biegelsen
Wells Fargo
Neutral
$69.00+18.7% to target
Coverage
—
+ Follow
INSP stock forecast FAQ
What is INSP's average 12-month price target?+
The 14 active firms with a live target average $67.07 for Inspire Medical Systems Inc over the next 12 months, ranging from a $97.00 high to a $39.00 low, as of Nov 19, 2026.
Is INSP stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 16 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 10 rate it Neutral, and 2 rate it Sell or Strong Sell.
What are the highest and lowest price targets for INSP?+
The Street-high target is $97.00 (Freedom Capital Markets), and the Street-low is $39.00 (UBS). The average of all 14 active-firm targets is $67.07.
How many active Wall Street firms cover INSP?+
16 active firms have a recognized rating on Inspire Medical Systems Inc as of Nov 19, 2026, and 14 active firms carry a live 12-month price target.
Who is the most accurate analyst covering INSP?+
Among analysts who currently cover INSP, Anthony Petrone of Mizuho has the strongest overall Quantellect track record (Rank #121). Their current call is Buy with a $75.00 target.
What is Inspire Medical Systems Inc's projected EPS for next quarter?+
The consensus estimate is $0.13 per share (range $-0.13 – $0.34) across 10 analysts. Full-year EPS is projected at $1.30, rising to $1.50 the following year.
How much revenue is Inspire Medical Systems Inc expected to report next quarter?+
Consensus revenue is $192.4M (range $184.8M – $200.3M). Full-year revenue is projected at $855.4M, growing to $877.8M next year.
Have analysts been upgrading or downgrading INSP lately?+
As of Nov 19, 2026, 4 of 16 active firms rate INSP a Buy (10 Neutral, 2 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INSP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.